RaySearch Laboratories AB (CHIX:RAYBS) Total Equity: kr1,043 Mil (As of Mar. 2026)


CHIX:RAYBS RaySearch Laboratories AB CHIX:RAYBS
95 GF Score
Price kr215.50
GF Value kr180.42
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB Total Equity?

RaySearch Laboratories AB CHIX:RAYBS 95 Total Equity is kr1,043 Mil as of Mar. 2026. GuruFocus rates CHIX:RAYBS with a GF Score™ of 95/100 and a GF Value™ of kr180.42 (Modestly Overvalued). The stock has 2 warning signs investors should review.

RaySearch Laboratories AB's total equity for the quarter that ended in Mar. 2026 was kr1,043 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

RaySearch Laboratories AB Total Equity Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB Total Equity Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 628.31 657.16 735.23 876.70 985.30

RaySearch Laboratories AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 921.97 848.93 919.30 985.30 1,042.70
CHIX:RAYBS
95GF Score
RaySearch Laboratories AB CHIX:RAYBS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

RaySearch Laboratories AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1992-1006.7
=985

RaySearch Laboratories AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2027.6-984.9
=1,043

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr1,043 Mil mean?
RaySearch Laboratories AB (CHIX:RAYBS) has a Total Equity of kr1,043 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for RaySearch Laboratories AB and its competitors.
Is RaySearch Laboratories AB's Total Equity too high?
RaySearch Laboratories AB's current Total Equity is kr1,043 Mil. Overall, RaySearch Laboratories AB has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Total Equity compare to VEEV and BTSG?
RaySearch Laboratories AB's Total Equity of kr1,043 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Healthcare Providers & Services company?
A good Total Equity depends on the Healthcare Providers & Services industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for RaySearch Laboratories AB and its competitors. RaySearch Laboratories AB's current Total Equity is kr1,043 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr180.42, compared to a current price of kr215.50 — trading 19.4% above its estimated fair value. The current Total Equity is kr1,043 Mil. RaySearch Laboratories AB's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Total Equity is kr1,043 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued. The current stock price of kr215.50 is trading 19.4% above its estimated GF Value™ of kr180.42. GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.

Key valuation signals for CHIX:RAYBS:

  • Total Equity: kr1,043 Mil
  • GF Value™: kr180.42 vs. price of kr215.50 (19.4% above fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
95GF Score

Get the complete analysis for CHIX:RAYBS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr215.50
Price
kr180.42
GF Value